Clinical Trial Update: A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease [Phase 3]

View source ↗

Summary

A Phase 3 multicenter open-label extension study evaluating the efficacy and safety of IBI311 in subjects with Thyroid Eye Disease (TED).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Eye Disease

Drugs mentioned

• IBI311

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Thyroid Eye Disease, TED | Phase 3 | Status: ACTIVE_NOT_RECRUITING